Influence of JAK inhibitors on the disease-associated network of intestinal immune cells in ulcerative colitis

Influence of JAK inhibitors on the disease-associated network of intestinal immune cells in ulcerative colitis - JAK inhibition in ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51787

Enrollment

Registered

2022-12-19

Start date

2022-12-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: ulcerative colitis indication for JAK inhibitor

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
Observing changes in molecular and cellular patterns in the biopsies and blood upon JAK inhibition using a multi-omics approach.	—

Secondary

Measure	Time frame
1. Which (pre-existing or treatment-related) molecular and cellular patterns correlate with response to treatment or lack thereof? 2. Are there differences between systemic (PMBCs) or local (biopsy) effects upon JAK inhibition? 3. What are the long term effects of JAK inhibition on the immunological environment (week 52)	—

Countries

Netherlands

Outcome results